Cargando…
Lack of correlation between thymidylate synthase levels in primary colorectal tumours and subsequent response to chemotherapy.
The increasing interest in 5-fluorouracil (5-FU) modulation and the development of new antifolates has focused attention in recent studies on the expression of the target enzyme thymidylate synthase (TS) as a determinant of drug sensitivity and resistance. Resistance to TS-directed drugs has been sh...
Autores principales: | , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group|1
1997
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2063401/ https://www.ncbi.nlm.nih.gov/pubmed/9062414 |
_version_ | 1782137329375248384 |
---|---|
author | Findlay, M. P. Cunningham, D. Morgan, G. Clinton, S. Hardcastle, A. Aherne, G. W. |
author_facet | Findlay, M. P. Cunningham, D. Morgan, G. Clinton, S. Hardcastle, A. Aherne, G. W. |
author_sort | Findlay, M. P. |
collection | PubMed |
description | The increasing interest in 5-fluorouracil (5-FU) modulation and the development of new antifolates has focused attention in recent studies on the expression of the target enzyme thymidylate synthase (TS) as a determinant of drug sensitivity and resistance. Resistance to TS-directed drugs has been shown to occur in vitro and in vivo with increased expression of the enzyme (determined by enzymatic assays as well as protein and gene expression assays). Several studies have evaluated the role of TS as a prognostic indicator of clinical response to chemotherapy containing TS-directed drugs. We have used a polyclonal antibody to recombinant human TS to establish a silver-enhanced immunogold staining method to localize TS in human tumours. Human tumour cell lines with acquired resistance to TS inhibitors owing to increased levels of TS were used to confirm the specificity of immunostaining. Stained sections were evaluated by image analysis. Immunostaining in tumour sections was greatly reduced (>80%) by preabsorption of the antiserum with recombinant TS. The method was used to determine the extent of TS immunostaining in 134 primary human colorectal tumours. The results were then compared with the clinical outcome and response to chemotherapy for the treatment of subsequent metastatic disease. A wide range (approximately 100-fold) of TS immunostaining was observed in these primary tumour sections. Normal mucosal tissue levels were 5-10 times lower than those observed in the adjacent tumour tissue. The values for TS immunostaining did not correlate with clinical endpoints, such as time from diagnosis to relapse, response to chemotherapy for disseminated disease, nor with Dukes' staging. This lack of correlation may be because this group of patients was selected on the basis of their need for palliative chemotherapy and did not include patients who were cured of their disease. Also, primary tumour TS expression may not give a good indication of the TS expression in metastatic lesions. The prognostic significance of TS protein expression in primary and metastatic lesions requires further evaluation. IMAGES: |
format | Text |
id | pubmed-2063401 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 1997 |
publisher | Nature Publishing Group|1 |
record_format | MEDLINE/PubMed |
spelling | pubmed-20634012009-09-10 Lack of correlation between thymidylate synthase levels in primary colorectal tumours and subsequent response to chemotherapy. Findlay, M. P. Cunningham, D. Morgan, G. Clinton, S. Hardcastle, A. Aherne, G. W. Br J Cancer Research Article The increasing interest in 5-fluorouracil (5-FU) modulation and the development of new antifolates has focused attention in recent studies on the expression of the target enzyme thymidylate synthase (TS) as a determinant of drug sensitivity and resistance. Resistance to TS-directed drugs has been shown to occur in vitro and in vivo with increased expression of the enzyme (determined by enzymatic assays as well as protein and gene expression assays). Several studies have evaluated the role of TS as a prognostic indicator of clinical response to chemotherapy containing TS-directed drugs. We have used a polyclonal antibody to recombinant human TS to establish a silver-enhanced immunogold staining method to localize TS in human tumours. Human tumour cell lines with acquired resistance to TS inhibitors owing to increased levels of TS were used to confirm the specificity of immunostaining. Stained sections were evaluated by image analysis. Immunostaining in tumour sections was greatly reduced (>80%) by preabsorption of the antiserum with recombinant TS. The method was used to determine the extent of TS immunostaining in 134 primary human colorectal tumours. The results were then compared with the clinical outcome and response to chemotherapy for the treatment of subsequent metastatic disease. A wide range (approximately 100-fold) of TS immunostaining was observed in these primary tumour sections. Normal mucosal tissue levels were 5-10 times lower than those observed in the adjacent tumour tissue. The values for TS immunostaining did not correlate with clinical endpoints, such as time from diagnosis to relapse, response to chemotherapy for disseminated disease, nor with Dukes' staging. This lack of correlation may be because this group of patients was selected on the basis of their need for palliative chemotherapy and did not include patients who were cured of their disease. Also, primary tumour TS expression may not give a good indication of the TS expression in metastatic lesions. The prognostic significance of TS protein expression in primary and metastatic lesions requires further evaluation. IMAGES: Nature Publishing Group|1 1997 /pmc/articles/PMC2063401/ /pubmed/9062414 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Research Article Findlay, M. P. Cunningham, D. Morgan, G. Clinton, S. Hardcastle, A. Aherne, G. W. Lack of correlation between thymidylate synthase levels in primary colorectal tumours and subsequent response to chemotherapy. |
title | Lack of correlation between thymidylate synthase levels in primary colorectal tumours and subsequent response to chemotherapy. |
title_full | Lack of correlation between thymidylate synthase levels in primary colorectal tumours and subsequent response to chemotherapy. |
title_fullStr | Lack of correlation between thymidylate synthase levels in primary colorectal tumours and subsequent response to chemotherapy. |
title_full_unstemmed | Lack of correlation between thymidylate synthase levels in primary colorectal tumours and subsequent response to chemotherapy. |
title_short | Lack of correlation between thymidylate synthase levels in primary colorectal tumours and subsequent response to chemotherapy. |
title_sort | lack of correlation between thymidylate synthase levels in primary colorectal tumours and subsequent response to chemotherapy. |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2063401/ https://www.ncbi.nlm.nih.gov/pubmed/9062414 |
work_keys_str_mv | AT findlaymp lackofcorrelationbetweenthymidylatesynthaselevelsinprimarycolorectaltumoursandsubsequentresponsetochemotherapy AT cunninghamd lackofcorrelationbetweenthymidylatesynthaselevelsinprimarycolorectaltumoursandsubsequentresponsetochemotherapy AT morgang lackofcorrelationbetweenthymidylatesynthaselevelsinprimarycolorectaltumoursandsubsequentresponsetochemotherapy AT clintons lackofcorrelationbetweenthymidylatesynthaselevelsinprimarycolorectaltumoursandsubsequentresponsetochemotherapy AT hardcastlea lackofcorrelationbetweenthymidylatesynthaselevelsinprimarycolorectaltumoursandsubsequentresponsetochemotherapy AT ahernegw lackofcorrelationbetweenthymidylatesynthaselevelsinprimarycolorectaltumoursandsubsequentresponsetochemotherapy |